In IgA nephropathy, oral methylprednisolone reduced adverse kidney outcomes but increased adverse events

Chi-Yuan Hsu; Raymond K Hsu

doi:10.7326/J22-0067

In IgA nephropathy, oral methylprednisolone reduced adverse kidney outcomes but increased adverse events

Ann Intern Med. 2022 Sep;175(9):JC105. doi: 10.7326/J22-0067. Epub 2022 Sep 6.

Authors

Chi-Yuan Hsu¹, Raymond K Hsu¹

Affiliation

¹ University of California, San Francisco, San Francisco, California, USA (C.H., R.K.H.).

PMID: 36063554
DOI: 10.7326/J22-0067

Abstract

Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327:1888-98. 35579642.

Publication types

Randomized Controlled Trial
Comment

MeSH terms

Glomerulonephritis, IGA* / chemically induced
Glomerulonephritis, IGA* / complications
Glomerulonephritis, IGA* / drug therapy
Glucocorticoids / adverse effects
Humans
Kidney
Methylprednisolone / adverse effects

Substances

Glucocorticoids
Methylprednisolone